Background: Triple negative breast cancer (TNBC) has been subclassified into multiple distinct immunophenotypic subtypes with variable clinical features. For example, in our previous study, TNBC with overexpression of CD24 in tumor cells and CD10 in tumor stromal cells was associated with both nodal and remote metastases . Prior studies have also shown that TNBC breast biopsies and metastases are molecularly heterogonous (Eur J Hum Genet. 2010,18:560). Given that mLNs are a target for adjuvant therapy, we sought to assess the stability of the mutation profile in primary and metastatic tumors from the same patients. Design: We studied paired breast primaries and synchronous mLN from 17 TNBC patients (pts, median ages: 51.5 years old). DNA from the paired samples was tested with a clinically-validated next generation sequencing (NGS) assay with 5% sensitivity for missense mutations, assessing mutations in 50 relevant target genes. BRAF V600E mutation was confirmed by Sanger sequencing. Results: Among the 34 samples from 17 pts, 39 non-synonymous mutations were identified (2.3/pt), including 30 that were present at both sites (concordant). Mutations were seen in TP53 (22/39, 56.4%), BRAF V600E (10%), PIK3CA (10%), MET (8%), APC and KDR in 2 each, and ATM, FGFR3, JAK3 and KIT in one case each. In 6 cases (35.3%), a total of 9 mutations were present in the breast biopsy but absent in mLN. These absent mutations include BRAF (V600E, 4), TP53 (4), PIK3CA (1) and APC (1). The discordant TP53 mutants were p.V274_C275del (2), p.R273H (2), p.E339* (1) and p.H179Q (1). Sanger sequencing of the breast samples in BRAF-mutated cases showed that V600E levels were high in 2 cases and low-level in 2. Discordant mutation status was unrelated to CD10 or CD24 expression but was associated with cases with higher mutation burden (2.83±0.55 versus 1.81±0.77, p<0.001).
Results: 42 of 47 (89.4%) of the sarcomas stained positive for COL18A1, 26(55%) of which had a staining intensity of moderate or greater. The sarcomas that lacked COL18A1 expression were undifferentiated sarcomas NOS (4) and pleomorphic rhabdomyosarcoma NOS (1). 45 of 48 (93.8%) sarcomas expressed PLOD2, 27 (56%) of which had at least moderate staining intensity. The sarcomas that lacked PLOD2 expression were undifferentiated sarcomas NOS (2) and pleomorphic rhabdomyosarcoma NOS (1). Conclusions: All human and mouse alveolar and embryonal rhabdomyosarcomas expressed significantly increased amounts of PLOD2 and COL18A1 relative to normal background tissue. While this pilot study analyzed only a small cohort of human tumors, it raises the possibility of eligibility for therapies targeting post-translational modifications of collagen, and suggests further human sarcoma subtypes to study for these markers.
Will the Quest for a Novel Positive Marker for a Diagnosis of Hirschsprung Disease on Formalin Fixed Rectal Mucosal Biopsies End with a Glucose Transporter? A Detailed Dual IHC Panel Study of GLUT1 and Calretinin
Maria F Bukelo, Usha Kini, Suravi Mohanty, Kanishka Das. St. John's Medical College and Hospital, Bangalore, Karnataka, India. Background: Hirschsprung disease (HD) is characterised by the aganglionosis of the rectum and its diagnosis is challenging due to the lack of a specific positive marker on formalin fixed paraffin embedded sections (FFPES) of rectal mucosa. Neither is AChE histochemistry (gold standard for HD diagnosis) suitable for FFPES nor is calretinin IHC, as it is a negative marker. Hence this study, to search for a novel positive IHC marker on mucosal FFPES for a definitive diagnosis of HD. Design: This cross sectional study was conducted on 20 full thickness FFPES of colon and 20 rectal mucosal biopsies; in 2 phases, each over a period of 6 months. In the first phase, 20 full thickness FFPES from resected ganglionic and aganglionic segments of HD were stained with H&E and GLUT1 (SPM498, Biocare) antibody and compared with the neuronal panel of Calretinin, Synaptophysin, CD56, NF, GFAP, S100 and PGP9.5. These were independently reported by 3 pathologist. The findings obtained were extrapolated to the second phase of the study for ratification, where subsequent 20 consecutive rectal mucosal biopsies, stained with H&E; GLUT1 and calretinin were studied (blind to the final diagnosis) and compared with the corresponding AChE stained sections. Results: Phase 1: GLUT1 stained the perineurium (PN) of serosal nerves in all segments and the PN of both submucosal and myenteric plexus nerves in aganglionic segments but was absent/minimal in the PN of ganglionic/normal colonic segments; ganglion cells were negative. Phase 2: Of the 20 rectal mucosal biopsies (9 HD and 10 Non-HD cases; 1 case inadequate after FFP embedding) studied, all 9 HD cases were diagnostic on GLUT1 staining which showed strong PN staining of small and large fibres in the submucosa. On the other hand, of the 10 Non-HD cases, 2 cases yielded a false positive diagnosis of HD by showing a strong PN staining of small nerve fibres in the submuscosa. Thus, while the NPV of an independent GLUT1 IHC marker for HD was 100%, its PPV was only 80%. However, when the GLUT1 sections were read with calretinin, a correct diagnosis was obtained in 100% cases as ratified by the AChE staining.
Conclusions:
The positive ring-like perineural staining of GLUT1 and negative staining of Calretinin are diagnostic of HD on FFPE rectal mucosal biopsies. A dual panel of GLUT1 and Calretinin IHC stains on FFPES could be as accurate as the gold standard AChE staining on frozen sections for the diagnosis of HD. Background: Dedicated cost-benefit analysis of universal Helicobacter immunohistochemical (IHC) staining in pediatric gastric biopsies has not been performed. As such, we undertook a morphologic study of pediatric Helicobacter cases with the intent to provide useful guidelines in the pediatric setting. Design: All Helicobacter positive gastric biopsies were retrospectively collected from our primary and referral care center over twelve months (63 cases) and 122 Helicobacter negative gastric controls were randomly selected from the same time period. All cases were reviewed and scored according to the Sydney System for the severity of acute and chronic inflammation, as well as the location of inflammation and presence of lymphoid follicles. Results: Within the reviewed 12 month period 1,979 total pediatric gastric biopsies were identified, including 63 Helicobacter positive cases (3.2%). We reviewed 185 biopsies (63 Helicobacter positive, 122 Helicobacter negative controls) and the corresponding Helicobacter IHC, which was performed in all cases. Helicobacter infection was significantly associated with lymphoid follicles (cases=42.9% vs. controls=4.1%, p<0.0001), active inflammation (cases=84.1% vs. controls=8.2%, p<0.0001), moderate or severe chronic inflammation in the oxyntic mucosa(cases=47.6% vs. controls=2.5%, p<0.0001) and any chronic inflammation in the antrum except inflammation that was both mild and superficial (cases=95.2% vs. controls=21.3%, p<0.0001). At least one of these inflammatory patterns was seen in all Helicobacter positive biopsies, compared with 34 of 122 control biopsies (100% vs. 27.9%, p<0.0001). Chronic active gastritis was present in 53 Helicobacter positive biopsies and 9 control biopsies (84.1% vs. 7.4%, p<0.0001).
A Strategy for Helicobacter Immunohistochemistry Utilization in the Pediatric

Conclusions:
We recommend performing Helicobacter IHC on pediatric gastric biopsies where organisms are not identifiable on H&E sections with any of the following inflammatory patterns: 1) lymphoid follicles, 2) any active inflammation, 3) moderate or severe chronic inflammation within the oxyntic mucosa, or 4) any chronic inflammation in the antrum except mild superficial inflammation. This approach can sensitively identify pediatric patients with Helicobacter gastritis while limiting IHC staining to approximately 30% of all gastric biopsies. In comparison with universal Helicobacter IHC, this approach would reduce patient charges at our institution by approximately $280,000 per year.
TdT-Positive Cells in Inflamed Pediatric Kidney: A Potential Diagnostic Pitfall
Jennifer Dunlap, Xavier Stacey, Sarah Click, Michael J Cascio, Megan Troxell. OHSU, Portland, OR. Background: We encountered a patient with infantile nephrotic syndrome associated with a dense mononuclear infiltrate and prominent extramedullary hematopoiesis (EMH). Immunohistochemical analysis revealed numerous Terminal deoxynucleotidyl Transferase (TdT) positive cells which raised concern for lymphoblastic lymphoma. EMH has been reported in the setting of dysplastic pediatric kidneys; however, to our knowledge, TdT expression has not been studied. Design: Pathology records were searched for pediatric nephrectomy or autopsy kidneys with inflammation (age 0-21). Slides were reviewed, with attention to EMH. The study group included 39 nephrectomy blocks from 36 patients, and 4 kidney blocks from 4 infant autopsies. Sections were stained for TdT by immunohistochemistry. TdT+ nuclei were quantitated (average of 3 maximal high power fields (hpf)). Dual immunostains for TdT/CD79a, TdT/CD3, and TdT/CD43 were performed in 6 cases with abundant TdT positivity. Results: TdT+ nuclei were present in 42 of 43 inflamed pediatric kidney blocks. TdT counts ranged from 1 to >200/hpf (mean 44.4). The presence and number of TdT+ nuclei showed a strong association with younger patient age, as did the presence of EMH (Table 1 Background: Diabetes Mellitus (DM) is one of the most common medical complications of pregnancy. Adverse perinatal outcome associated with pregestational DM include macrosomia and large placentas. While many previous diabetic pregnancy studies focused on the "large" aspects of the adverse outcome, in non-diabetic pregnancies the small-for-gestational (SGA) placentas exhibit increased rates of adverse perinatal outcomes. Current study investigated the clinicopathological correlation in SGA placentas from pregnancies complicated with type 1 DM (T1DM). Design: In this retrospective cohort study, we identified the subject population using registration statistics for the (state) Diabetes in Pregnancy Program (2003 Program ( to 2011 . SGA is defined as < 10 th percentile while appropriate-for-gestational age (AGA) as 10-90 th percentile. Categorical variables were compared by Chi-square 1 or Fisher's exact test 2 , and continuous variables were compared using t-test 3 . P<0.05 was considered statistically significant.
Results: 117 placentas from women with T1DM were identified, including 22 (18.9%) SGA and 63 (53.8%) AGA placentas. The placental weight and neonatal weight were significantly lower in the SGA group (P<0.0001) while the fetal-to-placental (f/p) weight ratio higher (P=0.03). The GA at delivery was significantly lower with SGA placentas (P=0.02). 12 (54.6%) SGA placentas were associated with f/p ratio > 90%tile, suggestive of exhausted placental functional reserve. There were more IUGR associated with SGA placentas (P=0.04). Histologically, there was more thrombosis of fetal vessels in the SGA placentas (P=0.004), suggestive of higher prevalence of fetal thrombotic vasculopathy. The SGA group had the only stillbirth case although statistical significance not reached (1/22 vs 0/63, P=0.26). Conclusions: SGA placentas are associated with significantly increased rates of IUGR, more f/p ratio > 90 th percentile and thrombosis of fetal blood vessels in placenta. The adverse outcome can include stillbirth. Further research is needed to elucidate mechanisms and consequences of SGA placenta and fetal circulation in T1DM. Closer attention should be given to gravida with T1DM and smaller placenta.
Frequent HRAS Mutations in Ectomesenchymoma (ECM): Overlapping Genetic Abnormalities with Embryonal Rhabdomyosarcoma (ERMS)
Shih-Chiang Huang, Rita Alaggio, Yun-Shao Sung, Narasimhan P Agaram, Cristina Antonescu. Memorial Sloan Kettering Cancer Center, New York, NY; Chang Gung Memorial Hospital, Taoyuan, Taiwan; Padova University Hospital, Padova, Italy. Background: ECM is an exceedingly rare pediatric sarcoma exhibiting a predilection for infants and young children. Microscopically the tumors harbour a biphasic phenotype composed of rhabdomyosarcoma (RMS) and a ganglioneuroma component. Although ECM is considered a neuroectodermal neoplasm with rhabdomyoblastic elements and classified under malignant nerve sheath tumors in the latest WHO, it remains unclear if its biology and clinical behaviour are closer to ERMS or malignant peripheral nerve sheath tumors (MPNST). Design: In this study we sought to investigate the genetic abnormalities of ECM and subjected 2 index cases to RNA sequencing. FusionSeq and Mutation detection algorithms for novel fusion gene discovery and oncogenic driver mutations, respectively, were applied. No fusion candidates were identified; but a recurrent pattern of mutations was noted which was then screened in 5 additional ECM cases. A control group of ERMS matched for age was tested for the same abnormalities. As the majority of MPNST show loss of H3K27me3 expression by IHC, we also assessed this marker in the ECM cohort. Results: All 7 ECM patients were male, with a mean age at diagnosis of 7.5 months (range 0.6-17 mo). All except one occurred in the pelvis/paratesticular region; one case arose in the hand. All cases showed a RMS component (positive for desmin, myogenin), which ranged from typical embryonal, spindle cell and occasionally undifferentiated/ round cell phenotype. The neuroectodermal elements (positive for S100, synaptophysin) were represented by scattered ganglion cells or areas of ganglioneuroma. Recurrent HRAS and PTPRD mutations were identified in both index cases, with one case also harbouring FBXW7 mutations. By Sanger sequencing, 6/7 (86%) cases had HRAS mutations (4, p.G13R; 2, p.Q61L) and 2 cases had PTPRD mutations. No additional cases showed FBXW7 mutations. No EED/SUZ12 mutations, typically seen in MPNST, were detected by RNAseq and H3K27me3 expression was retained. In the control ERMS group, 5/9 (56%) showed RAS mutations, equally distributed among HRAS, NRAS and KRAS hot spots. The available clinical data in 4 ECM patients showed long term uneventful survival (3-16 years) s/p RMS chemotherapy protocol. Conclusions: ECM shares frequent RAS mutations with ERMS of young age and retains H3K27me3 expression, suggesting a closer genetic link to RMS rather than MPNST. The good response to RMS chemotherapy and long survival corroborates this notion.
Prenatal Jarcho-Levin Syndrome
Ana Larque, Mar Bennasar, Paola Castillo, Alfons Nadal. Hospital Clinic, Barcelona, Spain; Barcelona Center for Maternal-Fetal Medicine and Neonatology, Hospital Clínic, Barcelona, Spain. Background: Jarcho-Levin syndrome is an eponym that has been used to describe a variety of clinical phenotypes consisting of short-trunk dwarfism associated with rib and vertebral anomalies. In this study, we show the longest prenatal series with Jarcho-Levin syndrome. Design: We retrospectively reviewed our institution's 2002-2014 prenatal autopsy and respective medical records for fetus with a Jarcho-Levin syndrome. Fetus history, autopsy and radiographic findings were recorded. Results: Ten fetal autopsies were identified. The fetuses were 7(70%) males and 3(30%) females with a median weeks' gestation of 21 (range, 14-25) . Two cases were not identified in the ultrasound antenatal diagnosis. Eight were spondylocostal dysostosis and 2 cases presented some bilateral and symmetrical fusion of the ribs at the costo-vertebral junction resulting in small thoracic volume and limited chest expansion that could correspond to a spondylothoracic dysplasia. Common autopsy findings include short necks, failure of formation and segmentation of vetebral bodies, and rib anomalies. Two cases presented a single umbilical artery. Seven cases were associated with congenital defects of which the most prevalent was renal anomalies. Conclusions: Advancements in prenatal medicine allow early diagnosis to provide appropriate genetic counseling. More studies are necessary to try to classify JarchoLevin syndrome at this early age. In pregnancy, the presence of preeclampsia (PE), systemic lupus erythematosus (SLE), and/or antiphospholipid antibodies (aPLA) is characterized by poor obstetric outcomes, with potential adverse effects for both the mother and fetus. While the histopathologic changes observed in these entities have been well established, the pathogenic mediators associated with tissue injury are poorly understood. The goal of this study was to investigate immunohistochemical (IHC) staining patterns in placentas of patients with PE, SLE, and aPLA using a panel of complement activation products and inflammatory biomarkers. Design: 40 placentas were evaluated, including 10 patients with a history of preeclampsia, 10 with SLE, and 10 with documented aPLA. 10 disease-free controls were selected based on an unremarkable clinical history and the absence of pathologic findings in the placenta. Multiple gestation pregnancies were excluded. Slides were reviewed and histology confirmed. Each case was evaluated with a panel of IHC markers including C3b, C4d, Annexin A5 (A5), and IgG. Staining was graded on intensity (0, 1+, 2+, 3+) and distribution (absent, patchy, diffuse). Results: C4d staining showed a distinct difference between disease groups and controls. 6/10 PE patients showed at least weak, focal staining for C4d, with 1 case showing near diffuse staining. 4/10 SLE patients showed at least weak, focal staining for C4d, with 1 case being strongly positive. 2/10 aPLA cases showed at least focal staining. All controls were negative. A5 staining showed intrinsic variability in all disease groups, while 10/10 controls showed diffuse, strong staining (2+ or 3+). C3b staining was variable within all groups but showed stronger staining in a larger number of cases in disease groups than controls. IgG staining did not show any significant difference among groups.
Group ( Conclusions: Previously, aPLA-associated pregnancy complications have been thought to be a consequence of a unique aPLA-mediated pathogenic mechanism. However, the similarity of the IHC findings in aPLA placentas to those from SLE and PE patients -i.e. increased complement deposition and decreased A5 staining -suggests that aPLA-associated pregnancy complications may reflect a more general autoimmune mechanism, such as localized deposition of immune complexes.
SOX10 Distinguishes Pilocytic and Pilomyxoid Astrocytomas from Ependymomas but Shows No Differences in Expression Level in Ependymomas from Infant Versus Older Children or between Molecular Subgroups
Abby M Richmond, Andrew M Donson, Nicholas K Foreman, Bette K KleinschmidtDeMasters. University of Colorado, Aurora, CO; Children's Hospital Colorado, Aurora, CO. Background: SOX10, a developmentally-regulated transcription factor with Olig 2 interaction, is important in non-neoplastic oligodendroglial development; mRNA transcripts and protein expression are, however, identified in a wider variety of central nervous system glial neoplasms than oligodendrogliomas. We previously showed by Affymetrix and Western blot analyses that high levels of SOX10 mRNA and protein exist in pilocytic astrocytomas (PA), but not ependymomas (EPN). We now extended these studies to investigate subsets of these two tumors known to affect infants: pilomyxoid astrocytomas (PMAs) and ependymomas <age 1 (iEPN), all EPN group A. We hypothesized that SOX10 transcripts might be lower in these generally moreaggressive tumors that affect infants. Design: Ten PMAs and 6 iEPN were compared with 21 PAs and 52 EPNs, groups A & B, supratentorial and myxopapillary in children >age 1.
Results: iEPNs and all EPNs in older children showed very low SOX10 expression levels, on average 7.1-fold below normal control tissues. EPN groups showed no significance in SOX10 expression between iEPN and EPN. PAs/PMAs had 24.1 /29.4-fold higher transcript levels, respectively, than normal tissues.
Recognizing the diagnostic potential this offered for distinguishing PA/PMA from EPN in clinical practice, we then applied SOX10 immunohistochemistry to PMAs, PAs, iEPNs, and EPNs from various anatomical sites, including adults to broaden the application. All PA/PMAs but none of 34 iEPNs/anaplastic supratentorial/spinal cord/posterior fossa/myxopapillary/subependymomas showed diffuse nuclear IHC+.
Conclusions:
Nuclear SOX10 IHC+ has significant diagnostic utility in distinguishing between PA and PMA from EPN, but does not differentiate infantile subtypes from similar tumors in older children.
BRAF Reactivity and BRAF Mutations in Pediatric Langerhans Cell Histiocytosis
Essia Saiji, Christelle Cerato Biderbost, Margaret Berczy, Anne-Laure Rougemont. Geneva University Hospitals, Geneva, Switzerland. Background: Langerhans cell histiocytosis (LCH) has a wide age range distribution, with a peak incidence in children aged 1-3 years old. Mutations in the BRAF gene have been described in LCH with an overall frequency of 48.5%, lending support to a neoplastic origin. BRAF activating mutations induce in mutated cells senescence pathways; in particular intense expression of the cell-cycle gatekeeper p16 INK4a has been shown in this setting. We assessed the expression of BRAF and senescence markers in a series of pediatric LCH, and compared the BRAF immunohistochemistry (IHC) results with Next Generation Sequencing (NGS) findings. Design: Twelve LCH cases from patients aged 2 to 17 years old (median 59 months) were sub-cutaneous in 4 patients, and located in bone in 8 patients. For IHC, we used the BRAF (V600E, Spring), p16
INK4a ( (SX118, DAKO) antibodies. Staining intensity was evaluated semi-quantitatively, and the percentage of positive LCH cells was determined. NGS was performed on DNA extracted from paraffin blocks using the Ion AmpliSeq™ Cancer Hotspot Panel v2 (Thermo Fisher), covering approximately 2,800 COSMIC mutations from 50 oncogenes and tumor suppressor genes. Variant analysis was performed using the "Gensearch NGS" software (Phenosystems). Tumor content varied from 30% to 90%. TaqMan assay was performed in one tumor where DNA amount was not sufficient for NGS Analysis. Results: Intense BRAF reactivity (2+ or 3+, in 80% to 100% tumor cells) was seen in 4 tumors, 3 of which occurring in bone. In all 4 tumors, NGS confirmed the presence of a BRAF V600E mutation, in a proportion of the tumor cells ranging from 15% to 70%. A further tumor showing no BRAF reactivity displayed a V600D BRAF mutation. Senescence associated proteins p16 and p21 showed reactivity in all tumors. Intense 3+ p16 nuclear reactivity was seen in 60% to 100% of the LCH cells, whereas p21 nuclear reactivity was of variable intensity (1+ to 3+), staining only a minority of the LCH cells (from 1% to 30%).
Conclusions:
In all 12 tumors correlation was observed between BRAF IHC findings and BRAF mutation status. Interestingly, the only patient displaying no BRAF IHC reactivity despite BRAF mutation showed a V600D mutation, in keeping with antibody specificity for V600E. Senescence associated protein (p16 and p21) reactivity was observed in all tumors, independent of the BRAF mutational status. Therefore, mechanisms other than oncogene-induced senescence are likely to be involved. Conclusions: Botryoid growth pattern is a relatively common finding in WT (about 10% in our large series). All histological types of WT can share this feature, and it appears in all stages. In the SIOP and COG staging criteria, the botryoid growth itself is not a criterion for stage II. The botryoid WT is not an entity but a pattern of tumor growth and these tumors should be sub-classified according to their overall histological features, which will determine treatment and prognosis.
High Level Expression of Divergent Endodermal Lineage Markers in Gonadal and Extragonadal Yolk Sac Tumors
Hadi Shojaei, Hong Hong, Raymond W Redline. University Hospitals Case Medical Center, Cleveland, OH. Background: Yolk sac tumors (YST), either pure or mixed with other elements, can occur in both gonadal and extragonadal (EG) sites. Divergent expression of endodermal lineage markers (ELM) may lead to delayed diagnosis as exemplified by a recent case of ovarian endometrioid-pattern YST with strong diffuse expression of TTF-1. The aim of this study was to assess the frequency, extent, and pattern of expression of three divergent ELM, TTF-1, CDX-2, and Hep-PAR1, in ovarian (OV), testicular (T), and EG YST before and after puberty. Design: All gonadal and EG YST from 1999-2013 were retrieved (N=26). Cases were separated by site (OV=5, T=15, EG=6) and age (prepubertal: EG=5, T=1, postpubertal: T=14, OV=5, EG=1). YST areas were defined as SALL-4+/Oct-4-. Relative proportion of 4 histologic patterns: microcystic, papillary, solid/myxoid, and glandular (enteric or endometrioid) was estimated. No polyvesicular vitelline or hepatoid foci were seen. Percent positivity for AFP, GLYP-3, TTF-1, CDX-2, and Hep-PAR1, was compared within YST areas according to site, age group, and histologic pattern.
Results:
The majority of YST (16/26) showed a predominance of the microcystic pattern. Most of the remaining YST had no predominant pattern. Testicular YST were all mixed type while 8/11 tumors from other sites were pure YST. All YST expressed AFP and GLYP-3. Mean percent positivity of AFP was highest in prepubertal YST (43% vs 18%) while mean percent positivity for GLYP-3 was uniform in all groups (~33%). High level (>25%) positive staining (HL+) for one or more divergent ELM was seen in 16/26 YST. HL+ TTF-1 was only seen in EG and OV YST (2/5 each), while HL+ Hep-PAR 1 staining was restricted to postpubertal tumors (8/20). HL+ CDX-2 staining (n=3) showed no age or site predilection. No case was HL+ for all 3 divergent ELM. Two cases were HL+ for TTF-1 and Hep-PAR 1 (both OV). One case was HL+ for TTF-1 and CDX-2 (EG) and one HL+ for CDX-2 and Hep-PAR 1 (T). No consistent pattern of divergent ELM expression by histologic pattern was observed. However, HL+ TTF-1 or CDX-2 expression was never seen in myxoid/solid areas and HL+ HepPAR-1 was predominantly observed in myxoid/solid and glandular areas. Conclusions: High level expression of one or more divergent ELM is seen in a majority of YST. Hep-PAR 1 positivity is less commonly used to interrogate tumors of unclear origin, but expression of TTF-1 and CDX-2 may create diagnostic confusion when not combined with other YST markers, particularly SALL-4. Background: Even with current therapy, metastatic rhabdomyosarcoma (RMS) shows a poor 5-year survival of only 30%. To search for potentially actionable mutations in FFPE tumor specimens, we have employed a targeted next-generation sequencing (NGS) panel. Design: Six cases of aggressive RMS were selected (ages: 2-20 yrs); 4 were metastatic at presentation and the others developed metastases within two years. Four cases harbored a PAX3-FOXO1 gene fusion characteristic of alveolar RMS. For each case, tumor and control tissues were analyzed in parallel. Sequencing was performed in a CLIA laboratory, using a panel of 409 cancer-related genes (~98% exon coverage). Results: Multiple mutations and gene amplifications were identified (Table 1) . MYCN, MDM2, and CDK4 amplifications were each seen in 50% of our fusion positive cases, and no amplifications were detected in either fusion negative case. Both patients with fusion positive tumors showing high level gene amplifications (ploidy 10) suffered a fulminant course. Mutations in the RTK/RAS/PI3K pathway were identified only in fusion negative cases. A TP53 mutation was seen in a fusion positive tumor.
Conclusions:
In accordance with previous studies, we found that tumors positive for PAX3 gene fusion showed amplification of cell cycle regulatory genes, whereas fusion negative tumors had mutations in the RAS/PI3K pathway. Remarkably, a potentially actionable alteration was found in every tumor -a high yield relative to reports of NGS in other tumor types. Our study shows that molecular profiling of RMS in a clinical setting is feasible, may yield prognostically useful information, and ultimately can guide treatment of this devastating disease.
Histopathological study on metastatic lesions of HBL has not been carried out sufficiently so far. We examined the clinicopathological features of primary and metastatic lesions of HBL to clarify the characteristic histology of metastatic lesions with multiple recurrences. Design: Seventeen HBLs with pulmonary metastasis/metastases were collected from archives of our institute. Histological review of subtype of both primary and metastatic lesions and a retrospective chart review of patients were carried out. Results: There were 11 boys and 6 girls. Average age at surgery were distributed between 1 year to 13 years. Nine patients were alive without disease, four were under treatment, and four were dead by disease. Histological specimens of the primary lesion after chemotherapy were available in 8 cases; four showed epithelial component only, and the remaining four showed mixed epithelial and mesenchymal components including osteoid formation. Metastasectomy was carried out 62 times in total (1-8 times/patient), and 336 pulmonary metastatic lesions were submitted (1-27 lesions/ one operation). Osteoid was found in the metastatic lesions of three patients, and in the other patients, the metastatic lesions were composed of only epithelial component. Background: Definition and classification of cystic lung diseases have been problematic with many overlaps in terminology. For intrapulmonary sequestration (IPS), diverse entities have been included because at present, its diagnosis is mostly dependent on the presence of feeding vessels. Additionally, relatively common occurrence of cystic adenomatoid features mimicking congenital pulmonary airway malformation, type 2, in pulmonary sequestration (PS) has led to case reports of "hybrid lesion", further complicating its definition. The aim of this study was to examine detailed histological features of pediatric PS at our institute and to clarify the spectrum of its histological findings. Design: During the period from 1970 to 2015, 136 pulmonary lesions submitted for pathological diagnosis at our institute were reviewed. Histological criteria for PS included aberrant elastic-type feeding artery, atretic ectopic bronchial tree, and ectopic hilar tissues (cartilage, mixed respiratory glands, lymph nodes). In addition, morphometric analyses of areas with cystic adenomatoid feature were carried out by using digital scanning system. Retrospective chart review of patients with histologically diagnosed PS were carried out. Results: In 21 of 136 pulmonary lesions, microscopic examination revealed aberrant elastic-type feeding artery and atretic ectopic bronchial tree near the entry of the feeding artery; 13 were intralobar (IPS) and 8 were extralobar lesions (EPS). Cartilage and/or mixed respiratory glands were noted around the elastic artery forming ectopic hilar tissues in 11 of 13 IPS and all 8 EPS. In 3 IPS, lymph nodes were present. Cystic adenomatoid features were observed in 17 of 21 PS cases (81%). Among 13 digitally scanned PS cases, 9 contained cystic adenomatoid features, ranging from 6% to 57% of the total area of PS in maximal cut section. The age of these patients at surgery ranged from 9 days to 14 years, and there were 10 boys and 11 girls. All patients except one girl were preoperatively diagnosed as PS on imaging study by the presence of feeding artery. In one exceptional patient, no feeding artery, but a cord-like substance, was identified on preoperative imaging study and during operation. Preoperative diagnosis for this patient was bronchial atresia. Conclusions: By thorough histological examination, the diagnosis of PS is possible even if the lesions show extensive inflammatory changes or have no overt feeding artery on imaging study. The present study showed the importance of ectopic atretic bronchial system and ectopic hilar tissues, which may be used to differentiate IPS from etiologically different ones. cases showed a range of fibroproliferative histology. Sixteen representative nodular cases, with cellular fascicular whorls resembling hypertrophic scar, from 15 patients were selected for immunohistochemical analysis with β-catenin, smooth muscle actin (SMA), desmin, and CD34. Results: Studied cases included 9 boys and 6 girls (mean age 7.9 years, range 1-20 years). Seven patients had congenital disorders of various types. Fifteen of 16 cases (94%) showed nuclear β-catenin positivity in areas corresponding histologically to spindle or stellate shaped cells arranged in poorly circumscribed whorls and short fascicles. This pattern composed the lesional tissue focally or almost entirely. SMA was restricted to areas of β-catenin positivity and stained less diffusely. Desmin was near absent, staining focally only in cases with predominant β-catenin positive areas. CD34 was negative in all β-catenin-positive areas, but highlighted adjacent mesenchyme. All cases were associated with tracheostomy, and 6 cases recurred after initial excision.
The tracheal lesions in this study demonstrated a fibroproliferative appearance indicative of a hypertrophic scar. Nuclear expression of β-catenin places these lesions in the spectrum of known hypertrophic scarring processes related to β-catenin dysregulation. Associated SMA expression is consistent with a wound healing process, whereby fibroblasts assume a myofibroblastic phenotype. The pattern of CD34 confirms previous findings for fibroproliferative lesions related to scarring. Awareness of these features should be considered to avoid misdiagnosis of desmoid tumor or dermatofibrosarcoma protuberans. Background: Rotavirus infection remains the most common cause of hospitalization and mortality in children due to the severe diarrhea and dehydration and causes more than 600,000 children deaths yearly worldwide. Net fluid loss caused by increased transport of sodium and chloride across the apical membrane of the gut lumen is well documented in the animal model of viral enteritis. However, the role of tight junction disruption and paracellular permeation in human rotavirus infection remains poorly understood. In this study, we measured the expression of tight junction associated proteins in vivo from rotavirus infected patients. Design: Eight patients were identified clinically and specimens were retrieved through copath from a period between 1984 to 2014 in the department of pathology, Wayne state University. Age matched normal colonic and small intestinal specimens were used as controls. Immunohistochemical stains against tight junction associated proteins claudin-8, myosin light chain kinase (MLCK), and phosphorylated light chain (p-MLC) were performed. The non-parametric Mann-Whitney analysis were employed to assess the IHC intensity scoring data.
Results: Claudin-8 expression was significantly decreased in the small intestine of rotavirus infected patients when compared to the normal cohort (p<0.05). However, expression in the colon although downregulated was not statistically significant. MLCK and p-MLC expression were increased in the small intestine and colon in patients with rotavirus infection however not clinically significant.
Claudin-8 expression is significantly decreased in the small intestine of patients with rotavirus infection which may indicate that tight junction dysregulation and disruption of paracellular permeation mediates rotavirus related diarrhea.
